Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Dificid Hits Sales Goal under Cubist Collaboration

Article Stock Quotes (2) Comments (0)

Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.

Analyst, Alan Carr, said, "Optimer reported $14.4M in 1Q12 Dificid net sales. Gross sales of $16.45M were preannounced in April. GAAP Diluted EPS of $(0.23) was above our $(0.63) estimate because of a $23.8M gain from OBI reconsolidation. The company also announced that it now expects to exceed the first year sales target under the Cubist (Nasdaq: CBST) commercialization deal, triggering recognition of incentive payments to Cubist. Management, however, did not provide Dificid sales or OpEx guidance. We continue to believe Dificid commercial potential is underappreciated." (Raising FY12 EPS loss from (1.92) to (0.99))

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $14.80 yesterday, with a 52 week range of $6.81-$17.95.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Goldman Sachs Downgrades Thoratec (THOR) to Neutral
• Deutsche Bank Raises PT on Access Midstream Partners (ACMP) to $57
• Goldman Sachs Upgrades Ruckus Wireless (RKUS) to Buy, 'Pullback Creates Opportunity'

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Needham & Company

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?